Phase III Study of


Journal

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410

Informations de publication

Date de publication:
04 2023
Historique:
received: 30 07 2022
revised: 27 10 2022
medline: 5 4 2023
pubmed: 24 11 2022
entrez: 23 11 2022
Statut: ppublish

Résumé

The objective of this study was to compare

Identifiants

pubmed: 36418170
pii: jnumed.122.264743
doi: 10.2967/jnumed.122.264743
pmc: PMC10071780
doi:

Substances chimiques

PSMA-1007 0
fluorocholine 6029HGL0QP
Gallium Radioisotopes 0
fluoromethylcholine 0
Radiopharmaceuticals 0

Banques de données

ClinicalTrials.gov
['NCT04102553']

Types de publication

Randomized Controlled Trial Multicenter Study Clinical Trial, Phase III Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

579-585

Informations de copyright

© 2023 by the Society of Nuclear Medicine and Molecular Imaging.

Références

J Nucl Med. 2016 Oct;57(Suppl 3):43S-48S
pubmed: 27694171
Eur Urol. 2020 Apr;77(4):403-417
pubmed: 30773328
J Nucl Med. 2015 Aug;56(8):1185-90
pubmed: 26112024
Am J Nucl Med Mol Imaging. 2019 Apr 15;9(2):127-139
pubmed: 31139496
Clin Nucl Med. 2013 Jan;38(1):e26-32
pubmed: 23242060
Arch Intern Med. 2010 Aug 9;170(15):1390-5
pubmed: 20696967
Eur J Nucl Med Mol Imaging. 2021 Dec;48(13):4483-4494
pubmed: 34120201
J Urol. 2021 Feb;205(2):356-369
pubmed: 32935652
Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):678-688
pubmed: 27889802
Eur Urol. 2018 Aug;74(2):179-190
pubmed: 29678358
Eur J Nucl Med Mol Imaging. 2022 Jun;49(7):2436-2444
pubmed: 35067735
Lancet Oncol. 2018 Oct;19(10):e534-e545
pubmed: 30303127
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):2935-2950
pubmed: 33416958
J Nucl Med. 2017 Mar;58(3):425-431
pubmed: 27789722
J Nucl Med. 2021 Feb;62(2):208-213
pubmed: 32817141
PLoS One. 2018 Feb 9;13(2):e0191487
pubmed: 29425221
J Nucl Med. 2019 Mar;60(3):362-368
pubmed: 30042163
Eur J Nucl Med Mol Imaging. 2012 Jun;39(6):936-43
pubmed: 22415598
Eur J Cancer. 2021 Nov;157:308-347
pubmed: 34560371

Auteurs

Pierre Olivier (P)

Nuclear Medicine and Nancyclotep Molecular Imaging Platform, CHRU-Nancy, Université de Lorraine, Nancy, France.

Anne-Laure Giraudet (AL)

Nuclear Medicine, LUMEN, Centre Leon Berard, Lyon, France.

Andrea Skanjeti (A)

Nuclear Medicine, HCL, Claude Bernard University-Lyon-1, Lyon, France.
Nuclear Medicine, Centre Hospitalier Sud Francilien, Corbeil Essonne, France.

Charles Merlin (C)

Department of Nuclear Medicine, Centre Jean Perrin, Clermont-Ferrand, France.

Pierre Weinmann (P)

HEGP-AP-HP, Nuclear Medicine, Université de Paris, Paris, France.

Ines Rudolph (I)

ABX Advanced Biochemical Compounds, Radeberg, Germany; and.

Alexander Hoepping (A)

ABX Advanced Biochemical Compounds, Radeberg, Germany; and.

Mathieu Gauthé (M)

Hôpital Tenon-AP-HP, Sorbonne Université, Paris, France mathieugauthe@yahoo.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH